S&P also assigned an “A+” long-term rating to PHS’ $100.5 million of series 2016A revenue bonds.
“The rating action reflects our view of PHS’ solid financial performance in fiscal 2015 and through the first three quarters of 2016, supporting a good balance sheet with continued growth in unrestricted reserves,” said S&P credit analyst Allison Bretz.
The outlook is stable, reflecting S&P’s opinion of PHS’ stable market position, year-over-year net patient revenue growth and adequate balance sheet metrics.
More articles on healthcare finance:
How CHS, Tenet, UHS, LifePoint and HCA fared in Q1
6 healthcare CFOs in the headlines
Gundersen Health System CEO, CFO: Health Affairs study on nonprofit hospitals ‘simply not true’
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
